Briefing
Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.
MRD-positive patients had inferior DFS (HR 15.75, 95% CI 12.59-19.68, P<0.0001). Those who remained positive 3 months after MRD detection were more than 5 times as likely to recur as those with clearance (HR 5.4, P<0.0001). Of 181 MRD-positive patients who received adjuvant therapy, 72.9% had clearance; 54% of those with later samples had sustained clearance, which was associated with far better outcomes than transient clearance (HR 32.57). A 50% or greater drop in MTM/mL at 6 months among treated MRD-positive patients was associated with better DFS (HR 2.39, P=0.004).
- n: 2,518 analyzed of 3,034 enrolled; MRD-window results in 2,093 (309 [14.8%] positive)
- Assay: Signatera (tumor-informed)